MAP2K7 and melanoma: For example, Ro-4987655, a highly selective mitogen-activated protein kinase kinase (MEK) inhibitor (38), has proved its efficacy in BRAF V600 mutant melanoma, BRAF wild-type melanoma, and KRAS mutant NSCLC patients (39).